Clinical trial AbbVie - M24-311
A phase 2, randomized study to evaluate the safety, efficacy and optimal dose ABBV-400 in combination with Fluorouracil (5-FU), Folinic Acid and Bevacizumab in previously treated subjects with unresectable metastatic colorectal (mCRC)
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | AbbVie |
| EudraCT Identifier | 2023-505110-14-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06107413 |
| Last update |